Thus, while existing drugs targeting PCSK9 and ABCA1 show that components of these pathways are pharmacologically tractable, their potential utility in preeclampsia would differ from current symptom-oriented approaches by directly modulating placental lipid transport and metabolic adaptation to hypoxia. This evidence concerns the gene ABCA1 and preeclampsia.